Centessa Pharmaceuticals (CNTA) to Release Earnings on Tuesday

Key Points

• Centessa Pharmaceuticals (NASDAQ:CNTA) is set to announce its Q2 2025 quarterly earnings on August 12th, with analysts expecting a loss of $0.34 per share.
• The company’s stock recently traded at $16.50 with a market cap of $2.20 billion, while insiders sold over $3 million worth of shares within the last three months.
• Currently, the average analyst rating for Centessa Pharmaceuticals is a "Moderate Buy" with a consensus price target of $28.10.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect Centessa Pharmaceuticals to post earnings of ($0.34) per share for the quarter.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.15. On average, analysts expect Centessa Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock traded down $0.31 during mid-day trading on Thursday, hitting $16.83. 333,456 shares of the company were exchanged, compared to its average volume of 958,626. The company has a market capitalization of $2.25 billion, a P/E ratio of -9.30 and a beta of 1.48. The business's 50 day simple moving average is $14.13 and its two-hundred day simple moving average is $14.46. Centessa Pharmaceuticals has a 12-month low of $9.60 and a 12-month high of $19.09. The company has a debt-to-equity ratio of 0.28, a current ratio of 14.37 and a quick ratio of 14.37.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 15,000 shares of the company's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $14.00, for a total transaction of $210,000.00. Following the completion of the sale, the insider directly owned 216,485 shares of the company's stock, valued at approximately $3,030,790. This represents a 6.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $12.71, for a total transaction of $699,050.00. Following the transaction, the chief executive officer owned 221,017 shares in the company, valued at approximately $2,809,126.07. The trade was a 19.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 230,322 shares of company stock worth $3,196,684. 7.09% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Centessa Pharmaceuticals stock. Millennium Management LLC raised its stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 52.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 609,188 shares of the company's stock after purchasing an additional 210,737 shares during the period. Millennium Management LLC owned 0.46% of Centessa Pharmaceuticals worth $8,760,000 as of its most recent SEC filing. Institutional investors own 82.01% of the company's stock.

Analyst Ratings Changes

CNTA has been the subject of several research reports. Chardan Capital reissued a "buy" rating and set a $30.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, July 30th. Truist Financial assumed coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a "buy" rating and a $30.00 price objective on the stock. Wall Street Zen raised shares of Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Needham & Company LLC assumed coverage on Centessa Pharmaceuticals in a research report on Wednesday, May 28th. They set a "buy" rating and a $35.00 price objective for the company. Finally, Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research note on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $28.10.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.